Efficacy and Toxicity of a Protocol Using Sirolimus, Tacrolimus and Daclizumab in a Nonhuman Primate Renal Allotransplant Model
Authors:
Open Access
- 1 April 2002
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 2 (4) , 381-385
Abstract
A regimen combining sirolimus, tacrolimus, and daclizumab has recently been shown to provide adequate immunosuppression for allogeneic islet transplantation in humans, but remains unproven for primar...Keywords
This publication has 13 references indexed in Scilit:
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) MONO- AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT SURVIVAL IN THE MONKEY1Transplantation, 2000
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Transplantation Tolerance: A Look at the Nonhuman Primate Literature in the Light of Modern Tolerance TheoriesCritical Reviews in Immunology, 1999
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998
- TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC TRANSPLANTATION IN THE RAT1,2Transplantation, 1997
- CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primatesProceedings of the National Academy of Sciences, 1997
- High‐resolution HLA‐DRB typing using denaturing gradient gel electrophoresis and direct sequencingTissue Antigens, 1997
- EFFECTS OF RAPAMYCIN IN EXPERIMENTAL ORGAN ALLOGRAFTINGTransplantation, 1993
- RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTINGThe Lancet, 1989